Avastin for PDR (Proliferative Diabetic Retinopathy)

Completed · Not applicable · Has a placebo group

Conditions studied: Retinal Detachment, Diabetic Retinopathy

In brief

The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).

Key facts

Study ID

NCT01270542

Run by

University of Southern California

People needed

20

Starts

2009-06-01

Expected to finish

2012-07-01

Last updated by the study team

2017-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Active fibrovascular proliferation due to PDR with TRD given pre-operative clearance for pars plana vitrectomy (PPV) and TRD repair.

You may not qualify if…

• Dense vitreous hemorrhage
• Inability to follow-up for surgery within 3-7 days after intravitreal injection
• History of stroke, thromboembolic event, or heart attack within the last 6 months
• Less than 18 years of age
• Pregnancy

Where it is running

• University of Southern California — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.